What is Pomella® Pomegranate Extract?
Patented Pomella® pomegranate extract delivers an ellagitannin rich profile standardized to punicalagin and polyphenol content and gut-derived metabolites to hone in on an array of antioxidant related health benefits. The antioxidant benefits of Pomella’s powerful polyphenols help support tangible health applications and contribute to overall wellbeing.
Key Attributes:
Punica granatum extract
Global intellectual property & multiple patents
Standardized to punicalagins
150 – 300mg / day
Clinically researched for a multitude of tangible health applications
What is Pomella® Pomegranate Extract?
Patented Pomella® pomegranate extract delivers an ellagitannin rich profile standardized to punicalagin and polyphenol content and gut-derived metabolites to hone in on an array of antioxidant related health benefits. The antioxidant benefits of Pomella’s powerful polyphenols help support tangible health applications and contribute to overall wellbeing.
Key Attributes:
- Punica granatum extract
- 150 – 300mg / day
- Global intellectual property & multiple patents
- Clinically researched for a multitude of tangible health applications
- Standardized to punicalagins
Pomella® Named Finalist for Nutrition Research Project Award
June 19, 2024
We’re proud to announce “Prospective, randomized, double-blind, placebo-controlled study of a standardized oral pomegranate extract [Pomella®] on the gut microbiome and short-chain fatty acids” has been honored as a finalist for the Nutrition Research Project category at the 2024 NutraIngredients-USA Awards.
The Next Frontier in Pet Health: Emerging Trends for Formulators
May 14, 2024
Pet ownership is at an all-time high, with 66% of US households owning at least one pet. From this, it’s no surprise that the global pet care market is estimated to grow from $246 billion in 2023 to $368 billion by 2030.
Breaking Boundaries: Insights Shaping Women’s Health
March 13, 2024
In the dynamic landscape of health and wellness, women’s health has been considered a niche market, despite women accounting for 80% of consumer purchasing decisions.
New Research: Pomella® May Support Gut Microbiome, Short Chain Fatty Acids, And Impact Mitochondrial Health
January 2, 2024
A new four-week, double-blind, placebo-controlled, randomized clinical trial evaluated 250mg/day Pomella®, a proprietary Punica granatum extract, in healthy men and women 25-55yrs (n=18, predominantly women) for beneficial effects on the gut microbiome, circulating short-chain fatty acids, and gut-microbial derived ellagitannin metabolites, namely urolithins, using whole genome sequencing for gut microbial analysis.
Pomella® Named Finalist for Nutrition Research Project Award
June 19, 2024
We’re proud to announce “Prospective, randomized, double-blind, placebo-controlled study of a standardized oral pomegranate extract [Pomella®] on the gut microbiome and short-chain fatty acids” has been honored as a finalist for the Nutrition Research Project category at the 2024 NutraIngredients-USA Awards.
The Next Frontier in Pet Health: Emerging Trends for Formulators
May 14, 2024
Pet ownership is at an all-time high, with 66% of US households owning at least one pet. From this, it’s no surprise that the global pet care market is estimated to grow from $246 billion in 2023 to $368 billion by 2030.
Breaking Boundaries: Insights Shaping Women’s Health
March 13, 2024
In the dynamic landscape of health and wellness, women’s health has been considered a niche market, despite women accounting for 80% of consumer purchasing decisions.
New Research: Pomella® May Support Gut Microbiome, Short Chain Fatty Acids, And Impact Mitochondrial Health
January 2, 2024
A new four-week, double-blind, placebo-controlled, randomized clinical trial evaluated 250mg/day Pomella®, a proprietary Punica granatum extract, in healthy men and women 25-55yrs (n=18, predominantly women) for beneficial effects on the gut microbiome, circulating short-chain fatty acids, and gut-microbial derived ellagitannin metabolites, namely urolithins, using whole genome sequencing for gut microbial analysis.
Pomella® Named Finalist for Nutrition Research Project Award
June 19, 2024
We’re proud to announce “Prospective, randomized, double-blind, placebo-controlled study of a standardized oral pomegranate extract [Pomella®] on the gut microbiome and short-chain fatty acids” has been honored as a finalist for the Nutrition Research Project category at the 2024 NutraIngredients-USA Awards.
The Next Frontier in Pet Health: Emerging Trends for Formulators
May 14, 2024
Pet ownership is at an all-time high, with 66% of US households owning at least one pet. From this, it’s no surprise that the global pet care market is estimated to grow from $246 billion in 2023 to $368 billion by 2030.
Breaking Boundaries: Insights Shaping Women’s Health
March 13, 2024
In the dynamic landscape of health and wellness, women’s health has been considered a niche market, despite women accounting for 80% of consumer purchasing decisions.
New Research: Pomella® May Support Gut Microbiome, Short Chain Fatty Acids, And Impact Mitochondrial Health
January 2, 2024
A new four-week, double-blind, placebo-controlled, randomized clinical trial evaluated 250mg/day Pomella®, a proprietary Punica granatum extract, in healthy men and women 25-55yrs (n=18, predominantly women) for beneficial effects on the gut microbiome, circulating short-chain fatty acids, and gut-microbial derived ellagitannin metabolites, namely urolithins, using whole genome sequencing for gut microbial analysis.
